Alphamab Oncology Stock

Detail Data
Volume (24h): 4,109,000 shares
P/E Ratio: 46.46
Forward P/E: -67.11
EPS: 0.26 HKD
Forward EPS: -0.18 HKD
Number of Shares: 970,394,697 shares
Market Capitalization: 11,722,368,000.00 HKD

Dividend

Dividend Value
Dividend Amount According to our data, the company Alphamab Oncology does not currently pay dividends.
Annual Yield %: -
Ex-dividend Date: -
5-Year Avg Yield %: -
Payout Ratio: -
Last Dividend Value: -
Last Dividend Date: -

Analyst Forecast

Most analysts have issued a none recommendation for Alphamab Oncology stock. The current number of analysts covering this company is 1. The highest target price is 6.9787498 HKD, while the lowest target price is 6.9787498 HKD. The median target valuation set by analysts is 6.9787498 HKD. These forecasts and recommendations provide insight into how analysts view the future stock performance of Alphamab Oncology.
Analysts Recommendation
Issued Recommendation: According to our data, the recommendation for Alphamab Oncology stock is: none
Number of Analysts: 1
Highest Target Price: 6.9787498 HKD
Lowest Target Price: 6.9787498 HKD
Median Target Price: 6.9787498 HKD

Fundamental Indicators

Indicator Data
Total Revenue: 785,960,000.00 HKD
Net Income: 232,812,992.00 HKD
Price-to-Book (P/B): 6.27
PEG Ratio: /
Exchange: HKSE
Industry: Biotechnology
Sector: Healthcare
Number of Employees: 484
Country: China

Where to Buy Alphamab Oncology Stock?

You can purchase Alphamab Oncology stock on the HKSE under the ticker symbol: 9966.HK. Several stock brokers or banks offer trading services for these stocks. Popular stock brokers like XTB and eToro allow you to buy real stocks and ETFs with zero or minimal commissions. Banks usually charge higher fees. Remember, investing in stocks involves risks, so it's important to carefully consider your financial situation and investment goals.

1

Real stocks and ETFs. Low minimum deposit, only 50 EUR. Option to copy trades. Advanced stock analysis and free education.

Trustpilot rating 4.4/5 Google play rating 4.2/5
Invest in Stocks with eToro
★★★★★ 5.0
2

Real stocks and ETFs + free demo account. Low fees + fast customer support. More than 5,200 instruments available for trading. Free training and education. Regular live streams on YouTube.

Trustpilot rating 3.6/5 Google play rating 4.5/5
Try Free Demo Account
★★★★☆ 4.8
Risk warning: Trading CFDs involves a high risk of financial loss. Between 51%-eToro -89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

More Information on Alphamab Oncology Stock

Indicator Value
Company Revenue: 785,960,000.00 HKD
EBITDA: 251,820,992.00 HKD - Positive EBITDA indicates profitable operations before interest, taxes, depreciation, and amortization.
Earnings Per Share: 0.26 HKD
Book Value Per Share: 1.93 HKD
Total Cash: 1,644,792,960.00 HKD
Total Cash per Share: 1.71 HKD
Total Debt: 273,481,984.00 HKD
Debt to Equity Ratio: 0.15
Quick Ratio 4.76
Current Ratio 4.98
Free Cash Flow 130,570,128.00 HKD
Operating Cash Flow 256,482,000.00 HKD
Gross Margins 92.27 %
EBITDA Margins 32.04 %
Operating Margins 0.20 %
Profit Margins 29.62 %
Return on Assets 5.2 %
Return on Equity 13.4 %
Earnings Growth (1 year) -
Revenue Growth (1 year) 84.0 %
Quarterly Earnings Year-over-Year Growth -
Market Capitalization 11,722,368,000.00 HKD
Enterprise Value 11,185,265,664.00 HKD
EV/Revenue 14.231
EV/EBITDA 44.418
Float Shares 490,293,438 shares
Shares Outstanding 970,394,697 shares
Held Percent Insiders 0.50 %
Held Percent Institutions 4.19 %
Shares Short -
Shares Short Prior Month -
Date Short Interest -
Short Percentage of Total Shares -
Short Ratio -
Beta 0.36
Short Percentage of Float -
Implied Shares Outstanding 970,394,697

Frequently Asked Questions (FAQ)

According to our data, the company Alphamab Oncology does not pay dividends yet, even in 2025.

Alphamab Oncology shares are traded on the HKSE stock exchange under the ticker: 9966.HK. You can buy or trade them through a variety of stock brokers who provide real stock trading services.

According to our data, the recommendation for Alphamab Oncology shares is from a total of 1 analysts. The average target price prediction is 6.9787498 HKD per share.

The total number of Alphamab Oncology shares on the exchange is 970,394,697.00 shares, which at the current market capitalization gives the company a total valuation of 11,722,368,000.00 HKD.